Results 31 to 40 of about 79,837 (298)

Characterization and in vitro data of antibody drug conjugates (ADCs) derived from heterotrifunctional linker designed for the site-specific preparation of dual ADCs

Data in Brief, 2018
Experimental procedures and 1H and 13C NMR of the heterotrifunctional linker used for preparation of dual drug conjugates and PBD payload are included.
Amit Kumar, Krista Kinneer, Luke Masterson, Ebele Ezeadi, Philip Howard, Herren Wu, Changshou Gao, Nazzareno Dimasi   +7 more
doaj   +1 more source

Process to Remove the Size Variants Contained in the Antibody–Chelator Complex PCTA-NCAB001 for Radiolabeling with Copper-64

Pharmaceuticals, 2023
Understanding the physicochemical properties of antibody–drug conjugates is critical to assess their quality at manufacturing and monitor them during subsequent storage.
Yukie Yoshii, Hiroki Matsumoto, Chika Igarashi, Tomoko Tachibana, Fukiko Hihara, Mitsuhiro Shinada, Atsuo Waki, Sei Yoshida, Kenichiro Naito, Kimiteru Ito, Tatsuya Higashi, Hiroaki Kurihara, Makoto Ueno   +12 more
doaj   +1 more source

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate

Drugs in R&D, 2018
Small cell lung cancer (SCLC) comprises about 15% of all cases of lung cancer. In recent years, owing to a change in the epidemiology of smoking habits, the incidence of the tumor has decreased; however, it remains a significant challenge to global ...
Bilal H. Lashari, Yazhini Vallatharasu, Lakshmi Kolandra, Mohsin Hamid, Dipesh Uprety   +4 more
doaj   +1 more source

Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review

Breast Cancer: Targets and Therapy, 2021
Anna S Linehan,1 Orla M Fitzpatrick,1 Patrick G Morris1,2 1Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; 2Department of Medical Oncology, Royal College of Surgeons in Ireland, Dublin, IrelandCorrespondence: Patrick G ...
Linehan AS, Fitzpatrick OM, Morris PG
doaj  

Crosstalk between the ribosome quality control‐associated E3 ubiquitin ligases LTN1 and RNF10

FEBS Letters, EarlyView.
Loss of the E3 ligase LTN1, the ubiquitin‐like modifier UFM1, or the deubiquitinating enzyme UFSP2 disrupts endoplasmic reticulum–ribosome quality control (ER‐RQC), a pathway that removes stalled ribosomes and faulty proteins. This disruption may trigger a compensatory response to ER‐RQC defects, including increased expression of the E3 ligase RNF10 ...
Yuxi Huang, Satoshi Hashimoto, Sota Ito, Chisato Kikuguchi, Miho Hoshi, Kiyoshi Yamaguchi, Yoichi Furukawa, Toru Suzuki, Toshifumi Inada   +8 more
wiley   +1 more source

Function‐driven design of a surrogate interleukin‐2 receptor ligand

FEBS Letters, EarlyView.
Interleukin (IL)‐2 signaling can be achieved and precisely fine‐tuned through the affinity, distance, and orientation of the heterodimeric receptors with their ligands. We designed a biased IL‐2 surrogate ligand that selectively promotes effector T and natural killer cell activation and differentiation. Interleukin (IL) receptors play a pivotal role in
Ziwei Tang, Zelin Cheng, Teng Li, Fulian Wang, Liangminghui Zhang, Xiuxiu He, Lili Liu, Wei Wang, Aibin Liang, Guang Yang   +9 more
wiley   +1 more source

Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1). [PDF]

PLoS ONE, 2015
The humanized monoclonal antibody-drug conjugate trastuzumab emtansine (T-DM1, Kadcyla) has been approved by the U.S. FDA to treat human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
Yuan-Chiang Chung, Jang-Fang Kuo, Wan-Chen Wei, King-Jen Chang, Wei-Ting Chao   +4 more
doaj   +1 more source

Inhibiting stearoyl‐CoA desaturase suppresses bone metastatic prostate cancer by modulating cellular stress, mTOR signaling, and DNA damage response

FEBS Letters, EarlyView.
Bone metastasis in prostate cancer (PCa) patients is a clinical hurdle due to the poor understanding of the supportive bone microenvironment. Here, we identify stearoyl‐CoA desaturase (SCD) as a tumor‐promoting enzyme and potential therapeutic target in bone metastatic PCa.
Alexis Wilson, Mackenzie K Herroon, Shane Mecca, Laimar C Garmo, Jacob Lindquist, Shrila Rajendran, Steve M. Patrick, Izabela Podgorski   +7 more
wiley   +1 more source

Application of Immuno-PET in Antibody–Drug Conjugate Development

Molecular Imaging, 2018
Targeted therapies hold great promise for cancer treatment and may exhibit even greater efficacy when combined with patient selection tools. The clinical impact of identifying likely responders includes reducing the number of unnecessary and ineffective ...
Kendra S. Carmon PhD, Ali Azhdarinia PhD
doaj   +1 more source

Pneumonitis as a side effect of breast cancer treatment: T-DXd and/or SBRT?

Liječnički vjesnik, 2023
Breast cancer that overexpresses the human epidermal growth factor receptor 2 (HER2) is considered to be HER2-positive. The novel HER2- directed antibody drug conjugate, trastuzumab deruxtecan (T-DXd), is formed by covalently joining the monoclonal ...
Džana Bjelić, Sara Bognar, Jelena Benčić, Manuela Bajan, Natalija Dedić Plavetić   +4 more
doaj   +1 more source